Business
Natera Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer Management
Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by Signatera in over 1200 plasma samples
About this update from Natera, Inc.
[{"type":"text","content":"Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by Signatera in over 1200 plasma samples\n\n\nAUSTIN, Texas, Oct. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, today announced the publication of a new study in Clinical Cancer Research demonstrating the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to assess tumor growth rates and predict patient survival in early-stage colorectal cancer (CRC). The full study can be found here.\n\n \n \n \n \n \n \n\n \nIn previous studies, Signatera was validated to detect early-stage CRC recurrence 8.7 months earlier than CT imaging (median lead time), simply based on positive or negative MRD status.1 Without treatment, more than 98% of MRD-positive patients go on to relapse.1-4 This new study replicates that previous test performance in a larger, multi-center cohort; but it also demonstrates that MRD-positive patients can be further stratified based on the quantity of circulating tumor DNA (ctDNA) found in the blood, in particular, how quickly those levels grow over time (ctDNA growth rate, or ctDNA velocity). \nEvery Signatera test report contains positive/negative MRD status as well as the mean number of tumor molecules observed per mL of plasma (MTM/mL). With serial testing, these quantities can be compared over time to calculate ctDNA velocity, a unique metric that Natera will make available to its customers.\n\"This study, the largest of its kind in stage III CRC, demonstrates that personalized and tumor-informed ctDNA analysis offers more value than just a positive or negative result,\" said Dr. Andres Cervantes, professor of medical oncology at the University of Valencia, Spain, and senior author of the study. \"The novel combination of ctDNA detection and growth rate assessment provides unique opportunities for guiding clinical decision making.\"\nThe publication describes a prospectively-collected, multicenter study of 168 stage III CRC patients undergoing curative intent treatment, with longitudinal MRD assessment before and after surgery, and then at regular intervals throughout adjuvant chemotherapy (ACT) and surveillance for up to 3 years (n=1204 samples).\nKey findings from the stu...